LUCIDUMOL A

ID: ALA1917739

Max Phase: Preclinical

Molecular Formula: C30H48O4

Molecular Weight: 472.71

Molecule Type: Small molecule

Associated Items:

Representations

Synonyms (1): Lucidumol A
Synonyms from Alternative Forms(1):

    Canonical SMILES:  C[C@H](CC[C@H](O)C(C)(C)O)[C@H]1CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CCC(=O)C(C)(C)[C@@H]1CC3=O

    Standard InChI:  InChI=1S/C30H48O4/c1-18(9-10-24(33)27(4,5)34)19-11-16-30(8)25-20(12-15-29(19,30)7)28(6)14-13-23(32)26(2,3)22(28)17-21(25)31/h18-19,22,24,33-34H,9-17H2,1-8H3/t18-,19-,22+,24+,28-,29-,30+/m1/s1

    Standard InChI Key:  LVGCWXNRZNCAJG-AMKDLFIQSA-N

    Associated Targets(Human)

    Bile acid receptor FXR 6228 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    HUVEC 11049 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    HeLa 62764 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Associated Targets(non-human)

    Bile acid receptor/Retinoic acid receptor RXR-alpha 16 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Molecule Features

    Natural Product: YesOral: NoChemical Probe: NoParenteral: No
    Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
    Chirality: NoAvailability: NoProdrug: No

    Drug Indications

    MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

    Mechanisms of Action

    Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

    Properties

    Molecular Weight: 472.71Molecular Weight (Monoisotopic): 472.3553AlogP: 6.03#Rotatable Bonds: 5
    Polar Surface Area: 74.60Molecular Species: NEUTRALHBA: 4HBD: 2
    #RO5 Violations: 1HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
    CX Acidic pKa: 13.85CX Basic pKa: CX LogP: 5.46CX LogD: 5.46
    Aromatic Rings: 0Heavy Atoms: 34QED Weighted: 0.51Np Likeness Score: 3.26

    References

    1. Grienke U, Mihály-Bison J, Schuster D, Afonyushkin T, Binder M, Guan SH, Cheng CR, Wolber G, Stuppner H, Guo DA, Bochkov VN, Rollinger JM..  (2011)  Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.,  19  (22): [PMID:22014750] [10.1016/j.bmc.2011.09.039]
    2. Ríos JL, Andújar I, Recio MC, Giner RM..  (2012)  Lanostanoids from fungi: a group of potential anticancer compounds.,  75  (11): [PMID:23092389] [10.1021/np300412h]

    Source